



11 OCTOBER 2013, 4:30 PM CET

Cardio3 BioSciences to participate at the KBC Securities Benelux Biotech Healthcare Conference in New York on November 13 & 14

Mont-Saint-Guibert, Belgium, - The Belgian biotechnology company Cardio3 BioSciences (C3BS), leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, announces its participation for 2013 edition of the KBC Securities Benelux Biotech Healthcare Conference in New York on November 13 & 14, 2013.

After a successful participation in 2012, Cardio3 will have another opportunity to present an overview of the Company's strategy and key development programs to multiple US institutional investors.

Dr Christian Homsy, CEO of Cardio3 BioSciences, commented: "We are glad to be able to present at this KBC seminar in New York. This is an excellent opportunity for us to continue to build the C3BS profile, as one of the world leaders in the field of regenerative medicine, with US investors. As a newly listed company we will continue to have a pro-active IR program in order to keep our current shareholders well informed and to broaden our potential shareholder base."

***** END *****

For more information contact:

Cardio3 BioSciences

Dr Christian Homsy, CEO

Anne Portzenheim, Communication Manager

www.c3bs.com

Tel : +32 10 39 41 00

aportzenheim@c3bs.com

Citigate Dewe Rogerson

Chris Gardner

Tel : +44 (0) 207 638 9571

About Cardio3 BioSciences

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.



Permanent information

PRESS RELEASE

11 OCTOBER 2013, 4:30 PM CET

The Company's lead product candidate C-Cure[®] is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure[®] consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle cells that behave identically to those lost to heart disease. This process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath^{®ez}, the most technologically injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences' shares are listed on NYSE Euronext Brussels and NYSE Euronext Paris under the ticker symbol CARD.

C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities. As a result, of these factors investors and prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or review any forward-looking statement, whether as a result of new information, future events or otherwise
